Frontera Therapeutics

Executive Summary

Frontera Therapeutics is a clinical-stage gene therapy company focused on developing innovative treatments for large-market and rare diseases in ophthalmology, cardiology, and neurology. Founded in 2019 and headquartered in Cambridge, MA, the company has rapidly advanced several programs into Phase II and Phase III clinical trials, demonstrating best-in-class potential. Frontera’s pipeline addresses significant unmet medical needs, leveraging proprietary gene therapy platforms to deliver safe, effective, and affordable therapies globally. The company's lead candidate in ophthalmology has shown strong efficacy and safety in earlier trials, positioning it for pivotal data readouts. With an international footprint and a commitment to scalable manufacturing, Frontera aims to transform the treatment landscape for debilitating conditions.

Upcoming Catalysts (preview)

• H2 2026Phase 3 interim data readout for lead ophthalmology gene therapy candidate70% success
• H1 2026Partnership or licensing deal for cardiology program50% success
• Q4 2026Series C financing round to support pipeline expansion80% success